Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Belantamab mafodotin induces immunogenic cell death within 24-hrs of administration in NDMM

Ioannis Ntanasis-Stathopoulos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the results of a study investigating the use of belantamab mafodotin in combination with lenalidomide and dexamethasone (Rd) in the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.